Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation

Pamala Jacobson, John Rogosheske, Juliet N. Barker, Kathleen Green, Juki Ng, Daniel Weisdorf, Ye Tan, Janel Long, Rory Remmel, Ronald Sawchuk, Philip McGlave

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Mycophenolate mofetil is used increasingly to provide immunosuppression after nonmyeloablative allogeneic hematopoietic cell transplantation. There is wide variability in the pharmacokinetics of mycophenolic acid (MPA), the active metabolite, and low concentrations are associated with rejection after organ transplantation. We hypothesized that low MPA was associated with poorer engraftment and a higher incidence of acute graft versus host disease. We evaluated the pharmacokinetics in 87 adult subjects undergoing nonmyeloablative-related and nonmyeloablative-unrelated hematopoietic cell transplantation who were receiving 1 g mycophenolate mofetil orally or intravenously every 12 hours plus cyclosporine (INN, ciclosporin). Subjects with an unbound MPA area under the curve (AUC) from 0 to 6 hours of less than 150 ng·h/mL had a higher cumulative incidence of grade II-IV acute graft versus host disease than subjects with a greater AUC (68% versus 40%, P = .02). An unbound AUC from 0 to 12 hours of less than 300 ng·h/mL was also associated with more frequent acute graft versus host disease (58% versus 35%, P = .05). There was no association between graft versus host disease and trough concentrations (P ≤ .62). A higher cumulative incidence of engraftment was associated with total MPA trough concentrations greater than 1 μg/mL (P < .01). All engraftment failures occurred in the cord blood recipients. About one half of subjects were below the unbound AUC target after oral dosing with nearly a 5-fold variability in AUC. Intravenous dosing achieved unbound targets better than oral dosing. The current practice of dosing with 1 g twice daily provides inadequate plasma concentrations in many patients, and doses of at least 3 g/d are likely necessary. Therapeutic monitoring of MPA concentrations with dose adjustment into the therapeutic target appears to be necessary for the most effective use of mycophenolate mofetil.

Original languageEnglish (US)
Pages (from-to)486-500
Number of pages15
JournalClinical pharmacology and therapeutics
Volume78
Issue number5
DOIs
StatePublished - Nov 1 2005

Fingerprint

Mycophenolic Acid
Cell Transplantation
Area Under Curve
Graft vs Host Disease
Cyclosporine
Incidence
Pharmacokinetics
Organ Transplantation
Fetal Blood
Immunosuppression

Cite this

Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. / Jacobson, Pamala; Rogosheske, John; Barker, Juliet N.; Green, Kathleen; Ng, Juki; Weisdorf, Daniel; Tan, Ye; Long, Janel; Remmel, Rory; Sawchuk, Ronald; McGlave, Philip.

In: Clinical pharmacology and therapeutics, Vol. 78, No. 5, 01.11.2005, p. 486-500.

Research output: Contribution to journalArticle

Jacobson, Pamala ; Rogosheske, John ; Barker, Juliet N. ; Green, Kathleen ; Ng, Juki ; Weisdorf, Daniel ; Tan, Ye ; Long, Janel ; Remmel, Rory ; Sawchuk, Ronald ; McGlave, Philip. / Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. In: Clinical pharmacology and therapeutics. 2005 ; Vol. 78, No. 5. pp. 486-500.
@article{3274915ab4d84b10b488b8ded864a850,
title = "Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation",
abstract = "Mycophenolate mofetil is used increasingly to provide immunosuppression after nonmyeloablative allogeneic hematopoietic cell transplantation. There is wide variability in the pharmacokinetics of mycophenolic acid (MPA), the active metabolite, and low concentrations are associated with rejection after organ transplantation. We hypothesized that low MPA was associated with poorer engraftment and a higher incidence of acute graft versus host disease. We evaluated the pharmacokinetics in 87 adult subjects undergoing nonmyeloablative-related and nonmyeloablative-unrelated hematopoietic cell transplantation who were receiving 1 g mycophenolate mofetil orally or intravenously every 12 hours plus cyclosporine (INN, ciclosporin). Subjects with an unbound MPA area under the curve (AUC) from 0 to 6 hours of less than 150 ng·h/mL had a higher cumulative incidence of grade II-IV acute graft versus host disease than subjects with a greater AUC (68{\%} versus 40{\%}, P = .02). An unbound AUC from 0 to 12 hours of less than 300 ng·h/mL was also associated with more frequent acute graft versus host disease (58{\%} versus 35{\%}, P = .05). There was no association between graft versus host disease and trough concentrations (P ≤ .62). A higher cumulative incidence of engraftment was associated with total MPA trough concentrations greater than 1 μg/mL (P < .01). All engraftment failures occurred in the cord blood recipients. About one half of subjects were below the unbound AUC target after oral dosing with nearly a 5-fold variability in AUC. Intravenous dosing achieved unbound targets better than oral dosing. The current practice of dosing with 1 g twice daily provides inadequate plasma concentrations in many patients, and doses of at least 3 g/d are likely necessary. Therapeutic monitoring of MPA concentrations with dose adjustment into the therapeutic target appears to be necessary for the most effective use of mycophenolate mofetil.",
author = "Pamala Jacobson and John Rogosheske and Barker, {Juliet N.} and Kathleen Green and Juki Ng and Daniel Weisdorf and Ye Tan and Janel Long and Rory Remmel and Ronald Sawchuk and Philip McGlave",
year = "2005",
month = "11",
day = "1",
doi = "10.1016/j.clpt.2005.08.009",
language = "English (US)",
volume = "78",
pages = "486--500",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation

AU - Jacobson, Pamala

AU - Rogosheske, John

AU - Barker, Juliet N.

AU - Green, Kathleen

AU - Ng, Juki

AU - Weisdorf, Daniel

AU - Tan, Ye

AU - Long, Janel

AU - Remmel, Rory

AU - Sawchuk, Ronald

AU - McGlave, Philip

PY - 2005/11/1

Y1 - 2005/11/1

N2 - Mycophenolate mofetil is used increasingly to provide immunosuppression after nonmyeloablative allogeneic hematopoietic cell transplantation. There is wide variability in the pharmacokinetics of mycophenolic acid (MPA), the active metabolite, and low concentrations are associated with rejection after organ transplantation. We hypothesized that low MPA was associated with poorer engraftment and a higher incidence of acute graft versus host disease. We evaluated the pharmacokinetics in 87 adult subjects undergoing nonmyeloablative-related and nonmyeloablative-unrelated hematopoietic cell transplantation who were receiving 1 g mycophenolate mofetil orally or intravenously every 12 hours plus cyclosporine (INN, ciclosporin). Subjects with an unbound MPA area under the curve (AUC) from 0 to 6 hours of less than 150 ng·h/mL had a higher cumulative incidence of grade II-IV acute graft versus host disease than subjects with a greater AUC (68% versus 40%, P = .02). An unbound AUC from 0 to 12 hours of less than 300 ng·h/mL was also associated with more frequent acute graft versus host disease (58% versus 35%, P = .05). There was no association between graft versus host disease and trough concentrations (P ≤ .62). A higher cumulative incidence of engraftment was associated with total MPA trough concentrations greater than 1 μg/mL (P < .01). All engraftment failures occurred in the cord blood recipients. About one half of subjects were below the unbound AUC target after oral dosing with nearly a 5-fold variability in AUC. Intravenous dosing achieved unbound targets better than oral dosing. The current practice of dosing with 1 g twice daily provides inadequate plasma concentrations in many patients, and doses of at least 3 g/d are likely necessary. Therapeutic monitoring of MPA concentrations with dose adjustment into the therapeutic target appears to be necessary for the most effective use of mycophenolate mofetil.

AB - Mycophenolate mofetil is used increasingly to provide immunosuppression after nonmyeloablative allogeneic hematopoietic cell transplantation. There is wide variability in the pharmacokinetics of mycophenolic acid (MPA), the active metabolite, and low concentrations are associated with rejection after organ transplantation. We hypothesized that low MPA was associated with poorer engraftment and a higher incidence of acute graft versus host disease. We evaluated the pharmacokinetics in 87 adult subjects undergoing nonmyeloablative-related and nonmyeloablative-unrelated hematopoietic cell transplantation who were receiving 1 g mycophenolate mofetil orally or intravenously every 12 hours plus cyclosporine (INN, ciclosporin). Subjects with an unbound MPA area under the curve (AUC) from 0 to 6 hours of less than 150 ng·h/mL had a higher cumulative incidence of grade II-IV acute graft versus host disease than subjects with a greater AUC (68% versus 40%, P = .02). An unbound AUC from 0 to 12 hours of less than 300 ng·h/mL was also associated with more frequent acute graft versus host disease (58% versus 35%, P = .05). There was no association between graft versus host disease and trough concentrations (P ≤ .62). A higher cumulative incidence of engraftment was associated with total MPA trough concentrations greater than 1 μg/mL (P < .01). All engraftment failures occurred in the cord blood recipients. About one half of subjects were below the unbound AUC target after oral dosing with nearly a 5-fold variability in AUC. Intravenous dosing achieved unbound targets better than oral dosing. The current practice of dosing with 1 g twice daily provides inadequate plasma concentrations in many patients, and doses of at least 3 g/d are likely necessary. Therapeutic monitoring of MPA concentrations with dose adjustment into the therapeutic target appears to be necessary for the most effective use of mycophenolate mofetil.

UR - http://www.scopus.com/inward/record.url?scp=28144433004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28144433004&partnerID=8YFLogxK

U2 - 10.1016/j.clpt.2005.08.009

DO - 10.1016/j.clpt.2005.08.009

M3 - Article

C2 - 16321615

AN - SCOPUS:28144433004

VL - 78

SP - 486

EP - 500

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -